Free Trial
Ends Tomorrow! Last Chance to Save $100 on MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim $100 Off
Claim MarketBeat All Access Sale Promotion

Amin Makarem Analyst Performance

Analyst at Jefferies Financial Group

Amin Makarem is a stock analyst at Jefferies Financial Group in the medical sector, covering 2 publicly traded companies. Over the past year, Amin Makarem has issued 5 stock ratings, including strong buy and buy recommendations. While full access to Amin Makarem's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Amin Makarem's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 0 Years
Buy Recommendations
100.00% 5 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy20.0%1 ratings
Buy80.0%4 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

Out of 5 total stock ratings issued by Amin Makarem at Jefferies Financial Group, the majority (80.0%) have been Buy recommendations, followed by 20.0% Strong Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
2 companies

Amin Makarem, an analyst at Jefferies Financial Group, currently covers 2 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

Amin Makarem of Jefferies Financial Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
100.0%

Amin Makarem's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Urogen Pharma stock logo
URGN
Urogen Pharma
4/24/2026Upgrade$24.11Strong-Buy
Urogen Pharma stock logo
URGN
Urogen Pharma
4/10/2026Initiated Coverage$20.53$40.00Buy
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
3/12/2026Reiterated Rating$4.92Buy
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
2/17/2026Initiated Coverage$5.55$12.00Buy
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
2/17/2026Initiated Coverage$5.56$12.00Buy